Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

被引:19
|
作者
Choi, Peter [1 ]
Farouk, Mourad [2 ]
Manamley, Nick [3 ]
Addison, Janet [3 ]
机构
[1] John Hunter Hosp, Dept Nephrol, New Lambton Hts, NSW 2305, Australia
[2] Amgen Europe GmbH, CH-6301 Zug, Switzerland
[3] Amgen UK Ltd, Cambridge, England
关键词
Anemia; Chronic kidney disease; Darbepoetin alfa; Dose conversion; Erythropoiesis-stimulating agent; Hematology; Hemodialysis; Medication switching; Pegylated erythropoietin beta; Retrospective study; ANEMIA; AGENTS;
D O I
10.1007/s12325-013-0063-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo. Eligible patients had received hemodialysis for a parts per thousand yen12 months and DA for a parts per thousand yen7 months. Data were collected from 7 months before until 7 months after switching treatment. DCR was calculated for patients with Hb and ESA data available in both evaluation periods (EP; Months 1 and 2 were defined as the pre-switch EP, and Months 6 and 7 as the post-switch EP). Red blood cell transfusions pre- and post-switch were quantified. Of 302 patients enrolled, 206 had data available for DCR analysis. The geometric mean DCR was 1.17 (95% CI 1.05, 1.29). Regression analysis indicated a non-linear relationship between pre- and post-switch ESA doses; DCR decreased with increasing pre-switch DA dose. The geometric mean weekly ESA doses were 24.1 mu g DA in the pre-switch EP and 28.6 mu g PEG-Epo in the post-switch EP. Mean Hb was 11.5 g/dL in the pre-switch EP and 11.4 g/dL in the post-switch EP. There were 16 transfusions and 34 units transfused in the pre-switch period, versus 48 transfusions and 95 units transfused post-switch. Excluding patients receiving a transfusion within 90 days of or during either EP, the DCR was 1.21 (95% CI 1.09, 1.35). In these hemodialysis patients switched from DA to PEG-Epo the DCR was 1.17 and 1.21 after accounting for the effect of transfusions. The number of transfusions and units transfused increased approximately threefold from the pre-switch to the post-switch period.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 25 条
  • [21] Evaluation of the US Oncology network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 μg every 2 weeks in both naive patients and patients switched from epoetin alfa
    Thames, WA
    Smith, SL
    Scheifele, AC
    Yao, B
    Giffin, SA
    Alley, JL
    PHARMACOTHERAPY, 2004, 24 (03): : 313 - 323
  • [22] A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease
    Roger, Simon D.
    Suranyi, Michael G.
    Walker, Rowan G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (08) : 2181 - 2187
  • [23] Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
    Provenzano, Robert
    Besarab, Anatole
    Wright, Steven
    Dua, Sohan
    Zeig, Steven
    Nguyen, Peter
    Poole, Lona
    Saikali, Khalil G.
    Saha, Gopal
    Hemmerich, Stefan
    Szczech, Lynda
    Yu, K. H. Peony
    Neff, Thomas B.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (06) : 912 - 924
  • [24] Unit dosing of darbepoetin alfa for the treatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients
    Bristoyiannis, G
    Germanos, N
    Grekas, D
    Hatzidimitriou, C
    Iatrou, C
    Memmos, D
    Moutafis, S
    Papachristoforou, K
    Papadoniou, A
    Pappas, M
    Sakellariou, GA
    Siamopoulos, KC
    Sombolos, K
    Stamatelou, K
    Stathakis, CP
    Stavgiannoudakis, G
    Stratigis, S
    Syrganis, C
    Tsakiris, D
    Valis, D
    Vlahojannis, JG
    Vlassopoulos, D
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (03): : 195 - 211
  • [25] Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis A prospective, randomized, double blind, parallel group study
    Miao, Bolong
    Isachkina, Alina Nikolaevna
    Shutov, Evgeny Viktorovich
    Selyutin, Alexander Alekseevich
    Kvitkova, Lyudmila Vladimirovna
    Shilo, Valery Yuryevich
    Vetchinnikova, Olga Nikolaevna
    Alexandrov, Ilya Vyacheslavovich
    Perlin, Dmitry Vladislavovich
    Zuev, Alexander Vasilievich
    Davydkin, Igor Leonidovich
    Mironova, Tatyana Pavlovna
    Solovyova, Olga Mikhailovna
    Tutin, Alexey Pavlovich
    Omelchenko, Alexey Mikhailovich
    Vareesangthip, Kriengsak
    Khadikova, Nadezhda Georgievna
    Li, Man
    Li, Xiang
    MEDICINE, 2022, 101 (47) : E31426